This section includes information and resources about Hypertension for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals- For Non-US and Non-UK Healthcare Media Only
New data confirm superior blood pressure reductions in diabetic patients treated with TWYNSTA® compared to amlodipine alone- For NON-US and NON-UK Healthcare Media Only
European Medicines Agency approves TWYNSTA® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours- For non-US and non-UK Healthcare Media Only
Combination therapy of telmisartan and amlodipine provides significantly better blood pressure lowering than either agent alone- For non-US and non-UK Healthcare Media only
European Committee for Medicinal Products for Human Use (CHMP) adopts Positive Opinion for TWYNSTA®, Boehringer Ingelheim’s new single pill combination hypertension treatment- For non-US and non-UK Healthcare Media